BioCentury | May 28, 2012
Clinical News

ETBX-011: Phase I/II data

...Phase I/II trial in 25 patients with refractory advanced CEA-expressing colorectal cancer showed that subcutaneous ETBX-011...
...Society of Clinical Oncology meeting in Chicago in June. Etubics Corp. , Seattle, Wash. Product: ETBX-011...
BioCentury | Mar 7, 2011
Clinical News

ETBX-011: Phase II started

...subcutaneous ETBX-011 given every 3 weeks in 12 patients. Etubics Corp. , Seattle, Wash. Product: ETBX-011...
Items per page:
1 - 2 of 2